Finland· FI-REL-REL5098

Apresolin

A hydralazine product, registered in Finland by Novartis Pharma Stein AG. The same ATC class is registered in 6 of our 19 countries.

ATC C02DB02

Checked against Fimea (Finland) on September 27, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about ApresolinAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Hydralazine is registered in 6 of 19 countries.

Countries holding a registration under ATC C02DB02 (hydralazine), each read from that country’s own register.

This record: Finland, from Fimea (Finland)
3 of them publish a price we can compare per daily dose

Search hydralazine products by name

Hydralazine · ATC C02DB02

6 / 19 countries

Canada
Finlandprice
Japan
Norwayprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Fimea (Finland)

Manufacturer: Novartis Pharma Stein AG
Country: Finland (FI)
ATC code: C02DB02
ATC class: Hydralazine
Defined daily dose: 0.1 g, O
Reimbursed: Not published by this register
Source register: Fimea (Finland)
Last checked: September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

163 interactions on record for hydralazine.

Graded by severity as the source publishes them — 145 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check hydralazine against other medicines How interaction checks work

Hydralazine · interactions on record

163 records

145 moderate
1 minor
17 info

Most severe, free to view

ThiethylperazinA04AB03moderate
DiphenhydraminA04AB05moderate
DronabinolA04AD10moderate
NabiloneA04AD11moderate

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same class

Other records under C02DB02

Hydralazine, as other registers publish it.

All hydralazine products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/c33b4215-db11-438e-a6b9-5edfdc0a4b1b
GET /v1/drugs/c33b4215-db11-438e-a6b9-5edfdc0a4b1b?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": "0.1",
  "form": "tabletti",
  "route": null,
  "ddd_unit": "g",
  "strength": "25 mg",
  "atc_label": "hydralatsiini",
  "ma_number": "2977",
  "auth_status": "Myyntilupa peruuntunut",
  "eu_ma_number": null,
  "fimea_rel_id": "REL5098",
  "authorised_at": "1966-02-09"
}

API reference MCP server Plans

See everything about hydralazine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console